A phase II study of pirarubicin in patients with advanced recurrent head and neck squamous cell carcinoma

P. H M De Mulder, P. Cappelaere, F. Cognetti, J. Verweij, J. H. Schornagel, J. B. Vermorken, A. Kirkpatrick, J. L. Lefebvre

Research output: Contribution to journalArticle

Abstract

Background: Head and neck squamous carcinoma (HNSCC) is a chemotherapy-sensitive tumour, but this sensitivity is not reflected in an impact on survival. The study of new drugs is therefore indicated. Pirarubicin (4′-O-tetrahydropyranyl-doxorubicin) has a higher preclinical index than doxorubicin, with low cardiotoxicity in animal models. Patients and methods: Twenty-six patients with squamous cell carcinoma of the head and neck and documented progression after or during previous chemotherapy were entered into the study. Two patients were ineligible for evaluation. Pirarubicin was given at a dose of 70 mg/m2 every 3 weeks. Results: Partial remission was seen in 1 of the 24 evaluable patients. The predominant toxicity was bone marrow depression, with leucopenia in 62% of the patients. One patient died due to a gastrointestinal haemorrhage during a period with WHO grade IV thrombocytopenia. Conclusion: On the basis of these results, pirarubicin cannot be recommended as second-line treatment in patients with recurrent and metastatic HNSCC. Its possible relevance for first-line treatment cannot be judged from these data.

Original languageEnglish
Pages (from-to)438-440
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Volume33
Issue number5
DOIs
Publication statusPublished - Sep 1994

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A phase II study of pirarubicin in patients with advanced recurrent head and neck squamous cell carcinoma'. Together they form a unique fingerprint.

  • Cite this

    De Mulder, P. H. M., Cappelaere, P., Cognetti, F., Verweij, J., Schornagel, J. H., Vermorken, J. B., Kirkpatrick, A., & Lefebvre, J. L. (1994). A phase II study of pirarubicin in patients with advanced recurrent head and neck squamous cell carcinoma. Cancer Chemotherapy and Pharmacology, 33(5), 438-440. https://doi.org/10.1007/BF00686275